Catalyst Event
AbbVie Inc (ABBV) · Other
From Akros SCHK HK-U.S. Biotech Index (ASHUBIO)
4/24/2026, 12:00:00 AM
Received a Complete Response Letter (CRL) from the FDA for the Biologics License Application (BLA) for trenibotulinumtoxinE, requesting additional information on manufacturing processes.
Korean Translation
미용 치료제 후보물질 트레니보툴리눔톡신E의 생물의약품 허가 신청(BLA)에 대해 FDA로부터 제조 공정에 관한 추가 정보를 요청하는 보완요구서(CRL)를 수령함.
Related Recent Events
WuXi Biologics (Cayman) Inc (2269) · Other
The U.S. Office of Management and Budget (OMB) is scheduled to publish a full list of 'biotechnology companies of concern' (BCCs) by December 18, 2026, under the BIOSECURE Act; High importance is justified by the potential for severe regulatory risk causing a >10% price impact scheduled.
12/18/2026, 12:00:00 AM
WuXi AppTec Co Ltd (2359) · Other
Ex-dividend date on May 13, 2026, for the 2025 final cash dividend of RMB 1.57927 per share (RMB 15.7927 per 10 shares); low impact estimated as price typically adjusts by the dividend amount, scheduled.
5/13/2026, 12:00:00 AM
Gilead Sciences Inc (GILD) · Earnings Release
Q1 2026 earnings release is scheduled for 2026-05-07. This event is estimated to have a high price impact as quarterly results often drive significant market volatility scheduled.
5/7/2026, 12:00:00 AM
Kenvue Inc (KVUE) · Earnings Release
Kenvue will announce its first quarter 2026 financial results before the market opens on May 7, 2026. Based on historical earnings volatility, a 5% price impact is expected.
5/7/2026, 12:00:00 AM
Pfizer Inc (PFE) · Earnings Release
Pfizer is scheduled to release its Q1 2026 earnings results before the market opens on May 5, 2026, scheduled.
5/5/2026, 12:00:00 AM
Vertex Pharmaceuticals Inc (VRTX) · Earnings Release
Vertex Pharmaceuticals is scheduled to announce its first-quarter 2026 financial results after the market closes on May 4, 2026. This earnings release is estimated to have a >=5% price impact, scheduled
5/4/2026, 12:00:00 AM